$ABBV ToppingWe broke out of an ascending wedge to an even steep ascending wedge and the RSI even on the monthly chart is oversold.
I see us falling soon, likely to test resistance turned support on the top of the channel at around 120.
ABBVD trade ideas
2/3/2022 NYSE (ABBV)Buy (Entry Price) above the black line and exit (Stop Loss) below the red line. Can take profit at the suggested Target Price.
Entry Price: $148.09
Target Price: $149.49
Stop Loss: $145.76
Top of the channel.Buffet just released their 13F. The fund dropped all their shares on ABBV and BMY. Both are at the top of the channel. Yellow line is my prediction.
$ABBV - DO NOT FOLLOW JOE TERRANOVA @CNBCJoe just recommended ABBV. Great company, way over valued and he would more likely be selling into your buying. Do not follow these fools.
I am up 20%. Should I fix the profit? Shares not puts.Let's vote. I am for selling and buying back on bounces from support levels. ???
$ABBV - Breaking ATH ? watch for calls > 138.5Weekly outside bar
Holding daily above 21ema
Looks like breaking all time high
Had fun watching this one run.We have a weak market and this one is quite holding up! Would want to see this close above 132-133 for long.
Close below support - Puts.
Im open to any critique. Please feel free to comment and tell me what you think!
AbbVie still bullish. ABBVGaining momentum and impulsing. This is good if you are bullish on this one. COVID paranoia is doing wonders for the pharma sector. It is very rare how a whole sector can benefit so much financially from mass hysteria.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
AbbVie bearish because it is under the curveAbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
stop loss is the blue line
Jaws of death and jaws of wealth.Look for price to eventually reach upper bound resistance $160-165. That would be my exit point.
AbbVie Announces U.S. FDA Granted Breakthrough Therapy DesignatiABBV: AbbVie Inc.
2022-01-04 08:15:00
AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer
Exactly What I Look ForShowing exactly what I look for when I make my trades. Experiences traders know what these indicators mean. Message me if you have any questions about any indicators my arrows are pointing at. With this amount of overlapping signs that point towards a price drop is what leads to my confidence in buying my OTM puts and making high returns.
New and veteran subscribers!! It has been a crazy year for me, I am 23 and bought my first house in May and I depleted my stock market funds to put money down on the house. I slowly saved up money to trade but was not smart with my options and took a lot of losses. Definitely in the red for 2021. I got extensive eye surgery months after buying my home, and most recently got a huge promotion at my job in amazon leading to a 100% increase in my salary.
Looking forward to 2022 and have made a personal new years resolution to make at least one publication a week the year of 2022 and looking to only provide the best charts with the most accurate indicators.
I want to wish everyone a happy new year!
ABBV BUY High Yield Growth Stock ABBV is a High Yield Growth Stock on the move.
ABBV engages in the discovery, development, manufacture, and sale of pharmaceuticals worldwide. The company's offerings include pharmaceutical products such as autoimmune and intestinal disease therapy, HUMIRA, adult plaque psoriasis treatment, SKYRIZI, and adult rheumatoid arthritis treatment, RINVOQ.
On December 8, Allergan, an ABBV company, announced that its product VUITYâ„¢, the first U.S. Food and Drug Administration (FDA) approved eye drop to treat presbyopia, is now available by prescription in pharmacies nationwide. This should add to the company's revenue stream.
On December 6, ABBV announced positive top-line results from its U-EXCEED phase-3 induction study regarding the usage of Upadacitinib (RINVOQ®) to treat Crohn's disease. This demonstrates the company's expertise and should enable the company to cater to patients with this disease.
$ABBV Bull Flag?Does the volume and the price look genuine to you? or am I being a paranoid?
Disclaimer: I don't have any positions
ABBV Ready for breakout? or hitting resistance?I think ABBV is hitting long time resistance and will complete its 3rd wave near 125.. It will find resistance at ATH and then come down to anywhere between 107 and 113 before completing 4th wave... really like the stock for dividend.
AbbVie: Breakout! Buying a re-test of supportAbbVie - Short Term - We look to Buy at 119.00 (stop at 114.50)
Previous resistance level of 119.95 broken. A move higher has resulted in prices breaking from the previous range and confirmed our bullish expectation. We have a Gap open at 118.86 from 03/12/2021 to 06/12/2021. Further upside is expected although we prefer to set longs at our bespoke support levels at 119.00, resulting in improved risk/reward.
Our profit targets will be 135.00 and 150.00
Resistance: 122.42 / 124.00 / 130.00
Support: 119.95 / 118.86 / 115.03
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
ABBV ShortTrendline Break
At Resistance Zone
Short Entry 108.4
Stop 113
Target 85
Risk management is much more important than a good entry point.
The max Risk of each plan should be less than 1% of an account.
I am not a PRO trader. I trade option to test my trading plan with small cost.
